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Antigen stimulation may be important for splenic marginal
zone lymphoma pathogenesis. To address this hypothesis,
the occurrence of stereotyped B-cell receptors was investigat-
ed in 133 SMZL (26 HCV+) compared with 4,414 HCDR3
sequences from public databases. Sixteen SMZL (12%)
showed stereotyped BCR; 7 of 86 (8%) SMZL sequences
retrieved from public databases also belonged to stereotyped
HCDR3 subsets. Three categories of subsets were identified:
i) "SMZL-specific subsets" (n=5), composed only of 12 SMZL (9
HCV- from our series); ii) "Non-Hodgkin’s lymphoma-like sub-
sets" (n=5), comprising 5 SMZL (4 from our series) clustering
with other indolent lymphomas; iii) “CLL-like subsets” (n=6),
comprising 6 SMZL (3 from our series) that belonged to
known CLL subsets (n=4) or clustered with public CLL
sequences. Immunoglobulin 3D modeling of 3 subsets
revealed similarities in antigen binding regions not limited to
HCDR3. Overall, data suggest that the pathogenesis of
splenic marginal zone lymphoma may involve also HCV-
unrelated epitopes or an antigenic trigger common to other
indolent lymphomas.  
Key words: splenic marginal zone lymphoma, B cell recep-
tor, immunoglobulin genes, hepatitis C virus.
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ABSTRACT
Introduction
Splenic marginal zone lymphoma (SMZL) is recognized by
the WHO classification as an individual entity.1,2 Based on the
association with HCV infection and autoimmunity,3 it is con-
ceivable that antigen stimulation may play a role in SMZL.4,5
Though several studies investigated usage of immunoglobulin
heavy chain variable (IGHV) genes in SMZL,5-9 and two SMZL
cases with highly similar HCDR3 have been previously
reported,10 at present no definitive immunogenetic clues for
antigen stimulation have emerged. 
In other B-cell malignancies, namely chronic lymphocytic
leukemia (CLL), non-random combinations of specific IGHV-
D-J genes lead to stereotyped complementarity determining
region 3 (HCDR3) of the B-cell receptor (BCR) in a significant
fraction of cases.11,12 Occurrence of stereotyped HCDR3 in
CLL is regarded as an indication of antigen stimulation during
disease development.13
The purpose of the present study was to investigate the
occurrence and patterns of stereotyped HCDR3 in a large
panel of SMZL.
Design and Methods
Patients
The study was based on a multi-institutional series of 133 SMZL
cases. Diagnosis of SMZL was based on criteria proposed by the
WHO classification1 and by Matutes et al.2 (with spleen histology in 40©F
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patients and with bone marrow histology coupled with flow
cytometry in 93). Patients provided informed consent in accor-
dance with local institutional review board requirements (IRB) and
the Declaration of Helsinki. The study was approved by the IRB
of the Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Analysis of IGHV-D-J, IGKV-J and IGLV-J rearrangements
in SMZL
Mononuclear cells were obtained from bone marrow (n=62
cases), peripheral blood (n=44), spleen tissue (n=25) or locoregion-
al lymph node (n=2). IGHV-D-J, IGKV-J and IGLV-J rearrange-
ments were amplified and directly sequenced from cDNA as pre-
viously reported.9,14 Sequences were aligned to ImMunoGeneTics
sequence directory using the IMGT V-QUEST analysis software15
to obtain IGV, IGD, IGJ gene usage, mutational profile, functional
status and CDR3 amino acid (AA) sequence.
Analysis of IGHV-D-J rearrangements and identification
of SMZL with stereotyped HCDR3
Using the multiple sequence alignment software ClustalX
(2.0),16 HCDR3 AA sequences from 133 SMZL were aligned to
each other and to 4,414 sequences derived from B-cell neoplasia
entities and retrieved from in-house and public databases (Online
Supplementary Table S1), regardless of usage of different IGHV
genes. Subsets of stereotyped HCDR3 were defined according to
the criteria proposed by Messmer17 and Stamatopoulos.11 AA
differences at the same HCDR3 position in cases within a subset
were also evaluated (volume, hydropathy index, and chemical
characteristics). Subsets not previously reported have been
assigned a number preceded by N ("Novel”). A difference in
HCDR3 length of greater than 3 AA was not allowed in the
same cluster. Nomenclature of previously reported subsets was
made according to Stamatopoulos11 and Murray.12 Subsets com-
posed of  3 or more cases have been defined as “confirmed”.11
Subsets composed of 2 cases were defined as “provisional” and
were characterized by identical IGHV/IGHD/IGHJ or
IGHD/IGHJ genes, shared junctional residues and/or restricted
light-chain CDR3.18
Antibody modeling
The PIGS web-server19 was used to model the immunoglobu-
lins (Igs) for which both light and heavy chains were sequenced.
In 3 cases (cases 3926, 4625 and PV3) in which no suitable tem-
plate for the H3 region was found, we used the Modeller20 ab-initio
loop modeling procedure to build 10 different H3 loop conforma-
tions for each Ig and then, among these, we selected the centroid.
Surface potentials were derived using the APBS software21 with
standard parameters. All pictures where generated using the
PyMol software (http://www.pymol.org).
Analysis of clinical data
The χ2 test and Fisher’s exact test were used to compare groups.
Overall survival (OS) and progression free survival (PFS) were
defined according to current criteria.22 Survival analysis was per-
formed by the Kaplan-Meier method, using Gehan–Wilcoxon sta-
tistics to test for significant associations. Cox’s analysis was used
to build a multivariate model. Analyses were carried out using
Stata SE 9 (StataCorp LP), Statistica 8 (StatSoft Inc.) and Microsoft
Excel 2000.
Results and Discussion
The clinical features of the 133 SMZL are summarized
in the Online Supplementary Table S2. Median age at diag-
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Table 1. IGHV, IGHD and IGHJ gene usage in 133 SMZL patients accord-
ing to IGHV identity.
IGHV gene N. of Identity Identity 
sequences <98% (n=93) ≥98% (n=40)
1-18 3 1 2
1-2 26 15 11
1-3 1 1 0
1-69 10 7 3
2-70 1 1 0
3-11 2 2 0
3-21 4 0 4
3-23 24 22 2
3-30 8 6 2
3-30-3 1 1 0
3-33 5 3 2
3-48 5 4 1
3-49 1 1 0
3-66 2 2 0
3-7 5 4 1
3-72 1 1 0
3-73 1 1 0
3-74 6 4 2
3-9 1 1 0
4-30-4 1 0 1
4-34 10 5 5
4-39 2 2 0
4-4 2 2 0
4-59 5 3 2
4-61 3 2 1
5-51 2 2 0
5-a 1 0 1
IGHD gene
1-1 1 1 0
1-26 3 2 1
1-7 2 1 1
2-15 3 2 1
2-2 7 5 2
2-21 3 2 1
2-8 5 2 3
3-10 6 5 1
3-16 4 1 3
3-22 15 13 2
3-3 24 15 9
3-9 5 5 0
4-17 3 2 1
4-23 5 5 0
4-4 1 1 0
5-12 4 2 2
5-24 3 2 1
5-5 4 1 3
6-13 5 3 2
6-19 7 5 2
6-25 1 0 1
6-6 5 2 3
NA 17 16 1
IGHJ gene
1 2 1 1
3 19 15 4
4 50 36 14
5 26 13 13
6 36 28 8
NA: not assignable.
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Table 2. SMZL-specific stereotyped HCDR3 subsets formed by HCV-negative SMZL cases from our cohort (complete dataset of stereotyped HCDR3 sub-
sets in SMZL are reported in the Online Supplementary Table S3).
SUBSET Average SMZL HCDR3 AA sequence (IMGT) IGHV IGHD IGHD IGHJ % IDENTITY IGLV IGLJ
intra-subset case reading to germline
identity (%) frame IGHV gene
N1 72.5
3926 C A R G P R I T I I G V V I - R G R G G G F D Y W IGHV1-2*04 IGHD3-3*01 3 IGHJ4*02 96,18 IGKV3-20*01 IGKJ4*01
4625 C A R G P R I S M I G V V I - N G R G G A F D Y W IGHV1-2*04 IGHD3-3*02 3 IGHJ4*02 96,72 IGKV3-15*01 IGKJ3*01
PV3 C A R G D R I T I F G V V I G N S R H G G F D Y W IGHV1-2*04 IGHD3-3*01 3 IGHJ4*02 98,61 IGKV3-11*01 IGJK5*01
* * * * * : : : * * * * . . *     * . * * *
N3 75
PV25 C A K D Y D Y L Y Y Y Y Y Y M D V W IGHV3-23*04 IGHD5-12*01 3 IGHJ6*03 95,83 IGLV1-40*01 IGLJ2/3
PV52 C A K D Q D D D Y Y Y Y Y G M D V W IGHV3-23*04 na IGHJ6*02 95,83 IGLV1-40*01 IGLJ2/3
* * * *         * * * * * * * *
N4 70.6
PV19 C A K D H N C S T Y Y Y Y Y Y Y D G W IGHV3-23*04 IGHD3-22*01 2 IGHJ6*03 95,83 IGLV1-44*01 IGLJ3*02
PV72 C A K D H N G N D Y Y Y Y Y G C D G W IGHV3-23*04 IGHD3-22*01 2 IGHJ6*04 95,14 IGLV1-47*01 IGLJ1*01
* * * * * .     * * * * * * *
Figure 1. (A) Three-dimensional
models of immunoglobulins
belonging to subsets N1, N3 and
N9. Antigen binding regions (panel
A) and mutation analysis (panels
B.1 and B.2) of modeled antibodies
are shown. In all cases, Igs belong-
ing to the same HCDR3 subset dis-
play an overall similarity, both in
sequence and structure, that is not
limited to the HCDR3 region.
Samples 3926, 4625 and PV3 in
subset N1 (panel A) have a positive-
ly charged antigen binding site
(Abs) with a protruding and
hydrophobic H3 loop (black arrow).
Subset N3 (cases PV25 and PV52,
panel A) presents nearly identical
Abs. A negatively charged pocket is
in the center of the binding site
(black arrow). Cases PV69 and
4468 (subset N9, panel A), though
presenting a less remarkable simi-
larity, share some common fea-
tures. The Abs is formed by a nega-
tively charged central protruding
region surrounded by a positive
area (black arrow). Panel B.1: com-
mon mutations (i.e. replacement of
the same specific residue of Igs in
the same group deriving from the
same germline) and convergent
mutations (i.e. replacement of a
residue in an Ig increasing its simi-
larity to another Ig belonging to the
same group but deriving from a dif-
ferent germline) are depicted in
green and red, respectively, on the
superimposed backbones of all the
Igs in each group. Blue circled area
highlights the most relevant muta-
tions; a close-up of the same region
is in panel B.2, where relevant
mutations are reported in a ball-
and-stick representation mapped
on a single representative structure
of each group. 
Correlated mutations are found on IGHV in subset N1, no significant correlation is evident on the light chains. Two common mutations (M33I
and A71V) are located in close proximity in the models and are likely to play a role in Abs specificity. Two similar mutations (S30BN and
S34N) are found in loop H1 of both samples belonging to subset N3 and may influence the H3 position and the Abs shape. Several mutations
on the heavy and light chains of both samples in subset N9 introduce polar and charged residues in the Abs. Sequence numbering follows
the Kabat-Chothia scheme.23 Abs are colored according to their electrostatic potential, ranging from −5 kBT/e (red) to + 5 kBT/e (blue). (B)
Hydrophobic areas of cases belonging to subset N1. Antigen binding sites of subset N1 immunoglobulins are depicted using the Kyte-
Doolittle hydropaticity score.24 Note the large hydrophobic patch found in the H3 loops of all samples (dark-green region) that is often asso-
ciated with an interaction area.
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nosis was 67 years (range 40-82). HCV serology was pos-
itive in 26 of 127 cases (20%). Five-year OS was 81% and
5-year PFS 46%.
Productive IGHV-D-J rearrangements were obtained
from all 133 SMZL cases. Use of IGHV, IGHD, and IGHJ
genes is reported in Table 1. The IGHV families most fre-
quently used were IGHV3 (n=66, 50%), IGHV1 (n=40,
30%) and IGHV4 (n=23, 17%). The IGHV genes most fre-
quently rearranged were IGHV1-2 (n=26, 20%), IGHV3-
23 (n=24, 18%), IGHV4-34 (n=10, 8%), and IGHV1-69
(n=10, 8%), confirming a biased VH gene usage in SMZL
as already suggested. Using the 98% identity cut-off value,
93 (70%) sequences were mutated and 40 (30%)
sequences were unmutated (15 with 100% identity, 10
with 99-99.9%, 15 with 98-98.9%).
By means of HCDR3 clustering analysis, 16 of 133
(12%) SMZL investigated in this study met the minimal
criteria to be included in subsets with stereotyped HCDR3
(Table 2 and Online Supplementary Table S3); 7 of 86 (8%)
SMZL sequences retrieved from public databases also
belonged to stereotyped HCDR3 subsets (Online
Supplementary Table S3).
On the basis of disease representation within individual
subsets, three major patterns of HCDR3 subsets were
identified: i) "SMZL-specific subsets", that included only
cases of SMZL; ii) "non-Hodgkin’s lymphoma (NHL)-like sub-
sets", that included cases of both SMZL and NHL in the
same subset; and iii) "CLL-like subsets", that included cases
of both SMZL and CLL in the same subset (Table 2 and
Online Supplementary Table S3).
The 5 SMZL-specific subsets were in all instances novel
subsets (confirmed: N1, N2; provisional: N3, N4, N5).
Nine HCV-negative SMZL cases from our cohort and 3
SMZL cases from public databases belonged to SMZL-spe-
cific subsets. The 5 NHL-like subsets (confirmed: N6, N7,
N8; provisional: N9, N10) were composed of 5 SMZL
cases (4 from this series) clustering with non-splenic MZL
and extranodal indolent lymphomas. Four SMZL (2 from
our series) clustered within known CLL subsets (subsets 1,
6, 9, 25) and two (one from our series) formed 2 novel pro-
visional subsets (N11, N12).
Three-dimensional models of Igs were produced for 3
subsets (2 SMZL-specific: N1, N3; 1 NHL-like: N9), after
obtaining light chain sequences (Online Supplementary Table
S3). Details of the modeling are reported in the Figure 1 leg-
end. In all cases, Igs belonging to the same stereotyped
group displayed an overall similarity, both in sequence and
structure, not limited to HCDR3. In particular, in subset N1,
a large hydrophobic area has been found on loop H3 (Figure
1) that is likely to be involved in antigen recognition.
HCV serology was negative in SMZL belonging to
SMZL-specific subsets and CLL-like subsets, whereas was
positive in 2/3 SMZL belonging to NHL subsets (P=0.02;
Online Supplementary Table S4). Median PFS was 1.7 years
(SE 0.5, 95% CI 0.7-4.7) for stereotyped cases and 5.3 for
non-stereotyped (SE 0.8, 95% CI 2.6-7.3) (P=0.06). Median
PFS was 2.7 years (SE 0.45, 95% CI 1.2-ND) for unmutat-
ed cases and 4.7 for mutated cases (SE 0.48, 95% CI 2.6-
ND) (P=0.06). By Cox’s regression analysis with mutation-
al status and stereotyped HCDR3 as covariates, both had
a significant effect on PFS (mutational status HR=1.8,
P=0.04; cluster HR=2.1 P=0.02).
These data point to the occurrence of SMZL-specific,
stereotyped HCDR3 sequences and Igs structures in
SMZL. Occurrence of stereotyped HCDR3 in both HCV-
negative and HCV-positive cases suggests that the poten-
tial role of antigens in SMZL pathogenesis is not restricted
to HCV, but may involve also HCV-unrelated epitopes
with a common BCR-binding signature. The role of anti-
gen stimulation in SMZL is further reinforced by the
observation that a fraction of SMZL share stereotyped
HCDR3 with non-splenic MZL and with CLL, suggesting
a potential common pathogenetic trigger in different indo-
lent B-cell malignancies.
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